GKGeorge Petrovich Kostyuk

George Petrovich Kostyuk

*This is an algorithmically generated author record based on publicly available information.

George Petrovich Kostyuk has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An impact of latent toxoplasmosis reactivation on immune system and clinical dynamics in patients with mild cognitive impairment

    by Irina K. Malashenkova, Sergey A. Krynskiy, Nikita A. Khailov, Andrey Y. Ratushnyy, Daniil P. Ogurtsov, Ksenia A. Chernyakova, Olesya V. Anufrieva, Dmitry B. Goncharov, Evgeniya V. Abbazova, Marina S. Baranets, et al.

    Mild cognitive impairment (MCI) in a number of cases precedes the development of dementia. Neuroinflammation is one of the key factors in neurodegeneration pathogenesis. Chronic infections and parasitic infestations contribute significantly to neuroinflammation. It has been evident about a link between systemic inflammation, disorders of cellular and humoral immunity and MCI progression. In this context, of particular interest is a role for a common intracellular pathogen Toxoplasma gondii may be involved in MCI pathogenesis and clinical dynamics. Currently, the frequency and clinical significance of toxoplasmosis reactivation in MCI remain unknown. Given Toxoplasma gondii-related immunotropic effects, it is also relevant to investigate an association between latent toxoplasmosis reactivation, immune parameters and inflammatory mediators in MCI. The study was aimed at assessing the frequency of chronic toxoplasmosis reactivation and its associations with cell immunity, levels of main cytokines and chemokines along with clinical dynamics in MCI. For this, individuals were divided into the following groups: main group included 130 patients with MCI, and comparison group — 81 patients with subjective cognitive impairment (preMCI). The serum was tested for anti-Toxoplasma gondii IgG, IgM, and IgA antibodies using enzyme-linked immunosorbent assay, the concentration of cytokines and chemokines was determined by multiplex assay. Cell immunity was assessed using flow cytometry. The Kruskal–Wallis test was used to assess the significance of differences, followed by pairwise comparisons with Mann–Whitney test. An increased frequency of latent toxoplasmosis reactivation (positive for anti-Toxoplasma gondii IgA in combination with IgG 50 IU/mL) was observed in MCI. In MCI patients, reactivation of toxoplasmosis was associated with impaired activation of Th1-cell immunity (lower total and subset T-cell counts including CD4+CD57+ T-cells and CD8+CD57+ T-cells), as well as increased levels and activation of NK-cells. Higher anti-Toxoplasma gondii IgG level in patients was associated with elevated neuroinflammatory markers CCL4 and CCL20, and with less favorable one-year-follow-up clinical dynamics. The results suggest that reactivation of latent toxoplasmosis in MCI may be clinically relevant, and it is important to determine not only anti-Toxoplasma gondii IgG and IgM, but also IgA to detect it.

  • Open Access

    Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease

    by A. N. Bogolepova, E. E. Vasenina, N. V. Vakhnina, S. V. Vorobyеv, S. I. Gavrilova, А. Yu. Emelin, V. V. Zakharov, S. N. Illarioshkin, O. V. Kosivtsova, G. P. Kostyuk, et al.

    Alzheimer's disease (AD) is the most common neurodegenerative disease and the most common cause of dementia. In daily practice, AD is often diagnosed late, while the early stages of the disease are overlooked or mistaken for cerebrovascular pathology. However, the efficacy of existing and newly developed (disease-modifying) AD therapies is the greatest in the early stages of the disease. An accurate diagnosis of AD is possible when biological markers of the main pathological process (cerebral amyloidosis, tauopathy) are detected using positron emission tomography or neurochemical examination of cerebrospinal fluid, which are gradually being introduced into practice in Russia. The experts discussed the clinical aspects of the use of biological markers, obtained in the leading specialized centers of our country for the diagnosis and treatment of cognitive impairment (CI). First and foremost, biomarker testing is indicated in patients with mild CI and mild dementia possibly associated with AD, so that disease-modifying (pathogenetic) therapy can be initiated as early as possible upon on its availability (currently, drugs for anti-amyloid disease-modifying therapy are not registered in the Russian Federation). Patients with a non-classical (non-amnestic) or atypical AD phenotype are another group of patients in whom it is also advisable to analyze biomarkers for differential diagnostic purposes.


  • Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI

    by I.K. Malashenkova, S.A. Krynskiy, D.P. Ogurtsov, N.A. Khailov, E.A. Filippova, S.N. Moskvina, V.L. Ushakov, V.A. Orlov, A.V. Andryushchenko, N.G. Osipova, et al.

    Objective. To study the relationship of the parameters of immunity and systemic inflammation with the structural magnetic resonance imaging (MRI) parameters in patients with mild cognitive impairment (MCI) and pre-MCI undergoing neurocognitive rehabilitation to search for candidate markers of its effectiveness. Material and methods. The main group included 49 patients, aged ≥60 years, with MCI and pre-MCI with memory impairment, who underwent a course of neurorehabilitation for 5 weeks. The control group included 19 volunteers of similar age with a total MoCA score of ≥25, who did not have cognitive impairment and immuno-inflammatory disorders. The parameters of cellular and humoral immunity and markers of inflammation were studied, and structural MRI was performed. Results. The content of activated natural killer cells (NK-cells) was increased in MCI and pre-MCI (0.63±0.12% vs. 0.22±0.07% in the control group, p=2.2·10–7). The level of immunoglobulin G (IgG) <12.5 g/l in patients with MCI and pre-MCI with the Montreal Cognitive Assessment Scale (MoCA) score <22 was associated with a decrease in the volume of the right nucleus accumbens (376±35 mm3 in patients with IgG <12.5 g/l (p=0.0013) and 480±44 mm3 at IgG <12.5 g/l, 480±44 mm3 in the control group), as well as with a decrease of the thickness and volume of a number of other cortical zones. A logistic regression model including the level of immunoglobulin G, NK cells, CD8+ NK cells and right amygdala volume was constructed to predict the number of MoCA scores 6 months after the course of rehabilitation (R2=0.57; p<1·10–5; standard error of estimate: 2.93). Conclusion. As a result of this work, the perspectives of assessing the immunological parameters in combination with socio-demographic data and morphometric changes of the brain as potential prognostic markers of the dynamics of cognitive impairment in patients with MCI and pre-MCI after neurorehabilitation has been shown.


  • Open Access

    Associations of IL17A G-197A single nucleotide polymorphism with immunological parameters and structural changes of the brain in schizophrenia

    by I. K. Malashenkova, V. L. Ushakov, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, A. Yu. Ratushnyy, E. A. Filippova, N. V. Zakharova, G. P. Kostyuk, Н. А. Дидковский, et al.

    Schizophrenia is a chronic mental disorder that is caused by a complex palette of genetic, epigenetic and environmental factors. Some of the important components of its pathogenesis are systemic inflammation and the dysfunction of immunity, which lead to neuroinflammation, contributing to development of structural brain changes. Earlier we have shown that increase in interleukin-17A levels is associated with morphometric changes and immune dysregulation in schizophrenia. IL17A G-197A (rs2275913) genetic polymorphism is involved in determining interleukin-17A secretion. The goal of this work was to investigate the associations between rs2275913 polymorphism, immune disorders and structural neurovisualization findings in schizophrenia to provide new insights into the immunopathogenesis of this disease. 60 patients aged 18 to 42 years diagnosed with schizophrenia were enrolled. 85 healthy volunteers were included into the control group. Multiplex assay was used to determine cytokine and chemokine serum levels. Rs2275913 polymorphism was assessed by polymerase chain reaction with electrophoretic detection of amplification products. A number of relationships between rs2275913 polymorphism and the immune parameters in schizophrenia were revealed. Carriers of G allele showed significant increase in IFNY, a key cytokine of Th1-link of adaptive immunity, and IL-8, an inflammatory chemokine. Also, increased levels of CXCL16 were observed in patients carrying the G allele. CXCL16 activates secretion of other proinflammatory chemokines and is involved in activation of Th1 adaptive immunity. Associations of heterozygous GA genotype with reduced cortical thickness in a number of areas of the frontal cortex in schizophrenia were found. Changes in cortical thickness in some of these areas, including middle frontal gyrus and orbitofrontal cortex, can be relevant to the pathogenesis of schizophrenia. The results highlight the importance of immunogenetic factors in the pathogenesis of schizophrenia and indicate that the rs2275913 polymorphism requires further studies as a potential biomarker of immune dysregulation and morphometric brain changes in schizophrenia.


  • Open Access

    Levels of chemokines and other inflammatory mediators in patients with mild cognitive impairment undergoing rehabilitation

    by I. K. Malashenkova, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, В. Д. Мельникова, A. V. Andryushenko, V. B. Savilov, M. V. Kurmyshev, G. P. Kostyuk, Н. А. Дидковский

    Alzheimer's disease is the most common neurodegenerative disease in old age. In some cases, it is preceded by mild cognitive impairment (MCI). One of the important components in the pathogenesis of neurodegeneration is chronic neuroinflammation (inflammatory activation of microglia and astrocytes in the brain). Systemic inflammatory response and immune dysregulation may contribute to neuroinflammation. The purpose of this study was to investigate the level of chemokines and other inflammatory mediators in patients with MCI who underwent medical rehabilitation, and to study its associations with the severity of cognitive impairment. The study group included 48 patients with MCI undergoing rehabilitation. Rehabilitation included cognitive therapy, psychotherapy and tasks for unaided performance. Repeated examination was conducted 6 months after the completion of rehabilitation. The control group included 46 healthy volunteers. Multiplex assay was used to determine serum cytokine and chemokine concentrations. Student's t-test was used to assess the significance of differences. Assessment of cognitive functions was performed using international neuropsychological scales. In patients with MCI, we have found an increase in the levels of several cytokines and chemokines (TNFα, CXCL10/IP10, MDC) that regulate systemic inflammation, cellular and humoral mechanisms of adaptive immunity. After the rehabilitation course their levels returned to normal. It was also found that decrease in CCL7 level in the patients before the rehabilitation course is associated with the severity of cognitive impairment. The findings contribute to understanding the role of chemokines in the pathogenesis of MCI, and indicate that their levels can be potential biomarkers of the severity of cognitive impairment. For translation of the findings into clinical practice, their validation in larger studies is needed, as well as assessing the associations between chemokine levels and the severity of cognitive impairment in MCI over long-term follow-up.


  • Open Access

    Association of IL-17A levels with immuneinflammatory profile and structural MRI data in patients with schizophrenia

    by I. K. Malashenkova, V. L. Ushakov, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, A. Yu. Ratushnyy, E. I. Chekulaeva, N. V. Zakharova, G. P. Kostyuk, Н. А. Дидковский, et al.

    IL-17A is a proinflammatory cytokine involved in pathogenesis of some neuroinflammatory diseases of the brain. However, its role in schizophrenia is poorly understood. Currently, noninvasive neuroimaging techniques are widely used to assess abnormalities in brain morphology and interactions of neuronal networks in schizophrenia. The aim of this work was to study associations between IL-17A level and brain morphometric parameters in schizophrenia, in order to clarify immune factors of pathogenesis and search for biomarkers of unfavorable disease course. 45 patients with schizophrenia and 30 healthy volunteers were included into the study. The levels of cytokines (IL-5, IL-6, IL-8, IL-10, IL-17A) and inflammatory markers were determined by ELISA or multiplex analysis. MRI scans were performed with a Siemens Magnetom Verio 3T MRI scanner. We used Kruskal–Wallis test to assess significant differences in immunological parameters followed by Mann–Whitney paired comparison; Student test to assess the significance of differences in morphometric parameters of the brain; Fisher exact test to assess the differences in discrete variables, with the differences considered statistically significant at p < 0.05. IL-17A levels were found to be increased in schizophrenia. Its elevated content was associated with increased levels of C-reactive protein, IL-5, IL-6, IL-8, IL-10, and the presence of morphometric changes of frontal and temporal cortex in the patients. So far, the relationships between IL-17A levels, immunoinflammatory parameters and structural brain changes have not been studied in schizophrenia. In the present work, we found an association of elevated IL-17A levels with decreased cortical thickness in several brain regions, systemic inflammation and activation of Th2-link of adaptive immunity in the patients with schizophrenia. According to the literature, a number of brain areas, where cortical thickness was associated with IL-17A levels may be relevant to pathogenesis of the disease and, in particular, to the development of negative symptoms, including impoverishment of interests, speech, and emotions. The results are important for understanding the role of immune disorders in pathogenesis of schizophrenia, including structural changes of the brain, and suggest that IL-17A may be a biomarker of these disorders. Confirmation of associations between structural neuroimaging findings, laboratory markers of inflammation and immune disorders may provide the basis for new multidisciplinary approaches to the diagnosis and prognosis of schizophrenia.


  • Fractures of the proximal femur. Clinical features, diagnosis and treatment (Clinical guidelines, abridged version)

    by Vadim E. Dubrov, Alexey A. Shelupaev, Gregory P. Arutyunov, Mikhail V. Belov, Anna S. Bogopolskaya, Svetlana A. Bozhkova, Alexandr V. Boyarkov, Tatyana N. Vorontsova, Sergey I. Gilfanov, Alexandr V. Gubin, et al.

    Proximal femoral fractures (PFF) are one of the most common reasons for admission of patients to a traumatological and orthopedic hospital. For the vast majority of patients with PFF, such injury means a loss of the previous degree of mobility. Clinical guidelines are the main working tool of a practicing physician, both a specialist and a narrow practice doctor. Conciseness, structuredness of information about a particular nosology, methods of its diagnosis and treatment, based on the principles of evidence-based medicine, allow to give in a short time one or another answer to a question of interest to a specialist, to achieve maximum efficiency and personalization of treatment. These clinical guidelines include data on the classification, clinical presentation, diagnosis, and treatment of proximal femoral fractures. In addition, they provide methods for the rehabilitation of patients with this pathology.


  • Open Access

    Intellectual decline in patients with schizophrenia with comorbid type ii diabetes mellitus and alcoholism

    by G. Р. Kostyuk, D. I. Cherepakhin, P. V. Aronov, G. N. Belskaya, I. A. Nikiforov, Г. П. Костюк

    Comorbid conditions in general psychopathological practice need equally research in the field of psychiatry and narcology, as well as the development of issues of social practice in relation to mental patients. There is an opinion that comorbid mental pathologies are even more common than “pure” forms of diseases. In most cases of comorbid conditions, the medical community increasingly encounters clinical situations where “classic” symptoms and syndromes are deformed, mutually intertwined and, superimposed on the actual social situation of the patient, acquire an “unreal fancy character”.Schizophrenia remains one of the most urgent problems at the stage of modern psychiatry formation. Up to date there are 1.1% of men and 1.9% of women in the general population of patients. Schizophrenic spectrum disorders are often combined with a number of chronic pathologies that increase the negative impact on the neuro-cognitive sphere of a person. One of the main problems of modern urbanized society is type II diabetes and alcoholism. By increasing the negative impact on a person’s cognitive abilities, they accelerate the process of disintegration of personality and its social functioning. The intellectual level of patients with those chronic diseases that require patients to actively and consciously participate in the treatment process and social functioning can significantly affect the patient’s ability to learn, independently manage the disease, establish a high level of compliance and, as a result, the effectiveness of therapy. An attentive study of the issue of the state of intelligence of patients with comorbid pathology will lead to an improvement in the patient’s social adaptation, a more careful attitude to their somatic health and reduce the risk of disability of the able-bodied population.

  • Questions of primary diagnosis of schizophrenia in middle-aged and older patients

    by G.P. Kostyuk, A.Yu. Berezantsev, L.A. Burygina, A.A. Zemskova

    An analysis of clinical and social characteristics of patients aged 40 years and older with primary diagnosis of schizophrenia (F 20-21) in a psychiatric hospital. We studied 114 medical records of patients aged 40 and over who were admitted to a psychiatric hospital for a two-year period (2018-2019) with a first-time diagnosis of schizophrenia (F 20-21) based on the results of inpatient examination and treatment. The analysis shows that 90% of patients were aged 40-59 years, 59.6% of them were women. In every third patient (33.3%), clinical signs of psychosis were observed for five or more years before hospitalization and diagnosis, and in 14.9% for more than 10 years, the average duration of psychosis before diagnosis was 5.1 years. Markers of psychosis were non-specific factors of family adaptation, working capacity, and substance use, which revealed relationships with gender characteristics and age of diagnosis of psychosis. Better adaptation parameters correlated with the female sex and later diagnosis of schizophrenia, lower indicators were more typical for the male sex and earlier diagnosis. Signs of increasing social maladjustment should be alarming to the patient's relatives, as well as social and medical services. In addition, the timely diagnosis of psychosis requires psychoeducation of the population, training of social workers and primary health care professionals.

  • Genotype — phenotype relationships in view of recent advances in the understanding of genetic causes of schizophrenia

    by V.E. Golimbet, G.P. Kostyuk

    Genotype - phenotype relationships are considered in view of recent advances in our understanding of genome structure. Different DNA elements can contribute to phenotype formation. Genotype - phenotype relationships are mediated by epigenetic effects that can have various origins - from the most studied to date methylation of certain sites in the genome to only developing ideas about the role of remote regulatory genomic elements in the development of schizophrenia. The transition to a more in-depth study of genotype - phenotype relationships is relevant for the current period of molecular-genetic studies of schizophrenia. Obviously, the concept of phenotype as applied to schizophrenia is not limited to a causal reflection of changes in the structure of a particular gene, but is the product of the combined effect of environmental factors and epigenetic changes that affect gene expression, taking into account tissue specificity and the degree of cell stimulation.